Join Paid Clinical Trials for Diabetes in Canada

Paid Clinical Trials and Focus Groups by Category

All Categories ... Medical Conditions » ... Diabetes » ... Canada

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes: An Extension Trial to NN1250-3579

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Exercise Program Combined or Not With Nutritional intErvention in Adults With tyPe 2 Diabetes

Conditions: Overweight; Obesity; Type 2 Diabetes
Interventions: Behavioral: Caloric restriction; Behavioral: Diet intervention and structured exercise training program
Sponsor: Institut de Recherches Cliniques de Montreal
Not yet recruiting - verified August 2010
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo
Sponsor: Novo Nordisk
Recruiting - verified September 2010
Efficacy of BI 10773 Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI10773; Drug: Placebo; Drug: Sitagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes

Condition: Diabetes Mellitus
Intervention: Device: NovoPen Echo®
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin aspart; Drug: insulin detemir; Drug: insulin aspart; Drug: insulin detemir
Sponsor: Novo Nordisk
Not yet recruiting - verified August 2010
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: LY2189265
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Sitagliptin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified June 2010
BI 10773 Cardiovascular Outcomes Trial in Type 2 Diabetes Mellitus Patients.

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)

Condition: Diabetic Macular Edema
Interventions: Drug: ranibizumab + laser photocoagulation; Drug: ranibizumab; Procedure: laser photocoagulation
Sponsor: Novartis
Recruiting - verified August 2010
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin; Drug: LY2189265; Drug: Placebo (oral); Drug: Placebo (subcutaneous)
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine

Condition: Acute Gout
Interventions: Drug: ACZ885 (Canakinumab); Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

Condition: Type 1 Diabetes Mellitus
Interventions: Biological: Otelixizumab; Biological: Placebo
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation; GlaxoSmithKline
Recruiting - verified May 2010
Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BMS-823778; Drug: BMS-823778; Drug: BMS-823778; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Canagliflozin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Placebo/sitaliptin 100 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Placebo; Drug: Glimepiride
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: linagliptin; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
A Study in Painful Diabetic Neuropathy

Condition: Diabetic Neuropathy, Painful
Interventions: Drug: Duloxetine; Drug: Pregabalin; Drug: Placebo
Sponsors: Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-2)

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin Glargine; Drug: LY2189265
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Conditions: Diabetes Mellitus, Type 2; Renal Insufficiency
Interventions: Drug: Canagliflozin 300 mg; Drug: Placebo; Drug: Canagliflozin 100 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Study Of Safety And Efficacy Of PF-04971729 In Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 1 mg PF-04971729; Drug: 5 mg PF-04971729; Drug: 10 mg PF-04971729; Drug: 25 mg PF-04971729; Drug: 100 mg sitagliptin
Sponsor: Pfizer
Recruiting - verified August 2010
Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

Condition: Diabetic Neuropathy, Painful
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified August 2010
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

Condition: Diabetes Type 2
Interventions: Drug: BMS-770767; Drug: BMS-770767; Drug: BMS-770767; Drug: BMS-770767; Drug: Placebo; Drug: Metformin
Sponsor: Bristol-Myers Squibb
Recruiting - verified May 2010
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
A Study is to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered Tapentadol ER at Dosages of 100 to 250 mg Twice Daily Compared With Placebo in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Conditions: Diabetic Neuropathy, Painful; Diabetic Polyneuropathy
Interventions: Drug: tapentadol extended release (ER); Drug: placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Grünenthal GmbH
Recruiting - verified August 2010
CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified August 2010
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified August 2010
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: linagliptin low dose; Drug: placebo; Drug: linagliptin medium dose
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Effect of Gastric Bypass on the Absorption of Metformin

Conditions: Obesity; Gastric Bypass
Intervention:
Sponsor: University of Alberta
Recruiting - verified August 2010
24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Sitagliptin
Sponsor: Sanofi-Aventis
Recruiting - verified September 2010
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo; Drug: insulin glargine (HOE901)
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Placebo; Drug: Hydrochlorothiazide
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified June 2010
Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified August 2010
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: JNJ-28431754; Drug: glimepiride
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin + metformin; Drug: Linagliptin+metformin; Drug: Metformin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified August 2010
An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics

Condition: Diabetic Neuropathies
Interventions: Drug: Placebo; Drug: Carisbamate 1,200 mg/d; Drug: Pregabalin 300 mg/d; Drug: Carisbamate 800 mg/d
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified August 2010
Incretin Effect and Use After Clinical Islet Transplantation

Condition: Type 1 Diabetes
Interventions: Drug: Pantoprazole; Drug: Sitagliptin
Sponsor: University of Alberta
Recruiting - verified August 2010
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)

Condition: Diabetic Foot Ulcer
Intervention: Drug: Fragmin
Sponsor: Pfizer
Recruiting - verified August 2010
Follow-Up Study for Exubera

Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified August 2010
Use of NPSP558 in the Treatment of Hypoparathyroidism

Condition: Hypoparathyroidism
Interventions: Drug: Placebo; Drug: NPSP558
Sponsor: NPS Pharmaceuticals
Recruiting - verified August 2010
Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients

Condition: Diabetic Foot Ulcer
Interventions: Drug: Fragmin/ Dalteparin Sodium; Drug: Placebo for Fragmin/ Dalteparin Sodium
Sponsor: Pfizer
Recruiting - verified August 2010
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease
Interventions: Drug: Aliskiren; Drug: Placebo
Sponsor: Novartis
Recruiting - verified August 2010
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Otelixizumab
Sponsors: Tolerx Inc.; Juvenile Diabetes Research Foundation
Recruiting - verified June 2009
Resistance Exercise in Already-active Diabetic Individuals (READI) Trial

Condition: Diabetes
Intervention: Behavioral: Resistance Exercise
Sponsors: Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Recruiting - verified August 2010

Join Paid Clinical Trials for Diabetes in Canada - Database

Join Paid Clinical Trials for Diabetes in Canada

Paid Clinical Trials and Focus Groups by Category

Featured Sponsors